Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

Valeant sales rise on deals; Regeneron's Eylea falls short; Dendreon, Ariad aided by cost cuts

08.05.2014 / Fierce Pharma

From a slight rise in revenue at the struggling cancer drugmaker Dendreon to a deal-fed increase at Valeant Pharmaceuticals to an against-the-odds upward tick at Germany's Stada, some smaller drugmakers are thumbing their noses at Big Pharma's downward trend this quarter.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: